Nice, France – As innovation in cancer diagnostics continues to advance, so does the need to ensure these tools are developed with the people they’re designed to serve. At last week’s GUIDE.MRD General Assembly in Nice, partners from across the scientific and clinical landscape gathered to share progress on the development of circulating tumour DNA (ctDNA) testing — also known as liquid biopsies — as a tool to support real-world cancer care.

LuCE (Lung Cancer Europe) joined the consortium to bring forward the vital perspective of those affected by lung cancer. The use of ctDNA testing is already informing treatment decisions in certain cancers. With further development, these minimally invasive blood tests could significantly enhance disease monitoring, enable earlier detection of recurrence, and guide clinical decision-making throughout the cancer journey.

“It was great to see the science and the patient perspective come together. These conversations help keep the focus on real-life impact,” said Chiara, LuCE Project Manager.

A highlight of the meeting was the meaningful contribution of Patient Advisory Board members Merel Hennink, Stephen Rowley, and Pietro Ravizzigno, who helped ensure patient voices remain central to the GUIDE.MRD mission.

LuCE extends sincere thanks to DiCE Europe, The Synergist, and all partners for their commitment to embedding patient engagement into the heart of innovation — across lung, colorectal, and pancreatic cancer.

GUIDE.MRD is supported by the IHI Innovative Health Initiative